Formulation and Evaluation Topotecan Encapsulated Gum Ghatti Nanoparticles

Abstract

Gum Ghatti (GG) nanoparticles containing Topotecan were the subject of this investigation to develop, optimize, and characterise them for use in cancer treatment. A solvent evaporation method involving aqueous and organic phases was used to make the nanoparticles. By adjusting various formulation and process parameters, the formulation was improved. Acetonitrile and phosphate buffer saline were used to develop the analytical method. To improve the nanoparticulate formulation, a variety of organic solvents and surfactants were evaluated. A Malvern zeta sizer was used to measure the size range and zeta potential. There were two distinct methods used for lyophilization, with a maximum drug entrapment rate of 35.2%. The dialysis method in phosphate buffer saline at a pH of 7.4 was used to evaluate the in vitro drug release of Topotecan nanoparticles. Over the course of 24 hours, the in vitro drug release demonstrated sustained drug release. As a result, GG nanoparticles loaded with Topotecan have the potential to serve as a drug delivery system. Due to their small size, they may also be able to reach extravascular target sites through the leaky endothelium of cancerous and inflamed regions, making them useful for site-specific drug delivery